RA is worst with temperature rising/ climate change. However SpA has the opposite effect! Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD

• https://x.com/bella_mehta/status/1933830002912424432/photo/1

Tips for Dx RP: 1. Suspect the dx and recognize chondritis. 2. Rule out mimickers 3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA) 4. CV, heme, derm manifestations 🧐VEXAS. 5. biopsy not useful unless ≠ from GCA. Fantastic session by @Lupusreference https://t.co/W4DgfeRULF

• https://x.com/AdelaCastro222/status/1933830357784183118/photo/1
• https://x.com/AdelaCastro222/status/1933830357784183118/photo/1
• https://x.com/AdelaCastro222/status/1933830357784183118/photo/1
• https://x.com/AdelaCastro222/status/1933830357784183118/photo/1

#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl

• https://x.com/Yuz6Yusof/status/1933830490508918907/photo/1

What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory? Rx Retro study 388 patients RA 18% at least one sign CPPD ns diff between seeonegative and seropositive pts RA+CPPD group was -older -higher comorbidity score -more likely to be https://t.co/DaW5DZoDzF

• https://x.com/AurelieRheumo/status/1933830991023366486/photo/1

Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 https://t.co/HtHyADsOSX

• https://x.com/bella_mehta/status/1933831254010388613/photo/1

Climate Change Impacts #Rheumatology Care Taking HEAT 🥵 causes: 🔺️⬆️ Hospitalisations 🔺️Renal failure ⚠️ NSAIDs 🔺️Flooding: no access to healthcare 🔺️New Infectious diseases mimics RMDs: Zika... 🔺️Insecurities for drug storage and transportation #EULAR2025 @RheumNow https://t.co/V9RyxYX6Me

• https://x.com/Nellziade/status/1933831739765395497/photo/1

APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010 https://t.co/LLN1TXvOC3

• https://x.com/DrMiniDey/status/1933831530633162911/photo/1

#GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN

• https://x.com/Janetbirdope/status/1933861026593902757/photo/1
• https://x.com/Janetbirdope/status/1933861026593902757/photo/1

Genicular artery embolisation is like so many interventions in MSK medicine: early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit. If you do meta-analyses of all these data, you mix good with bad #EULAR2025 @RheumNow https://t.co/K1tN9KX8rq

• https://x.com/drdavidliew/status/1933831819834638759/photo/1

Management and prognosis of RP by @Lupusreference 1. Pts with mild disease respond to GCs 2. NSAIDs/colchicine good alternatives 3. Most common biologics used: TNFi and IL6i 4. Consider CYP in life threatening dz/ICU pts 5. Dynamic CT assess tracheal collapse. 6. PET-CT can ≠ https://t.co/PNUecMZvkT

• https://x.com/AdelaCastro222/status/1933832435839455637/photo/1
• https://x.com/AdelaCastro222/status/1933832435839455637/photo/1
• https://x.com/AdelaCastro222/status/1933832435839455637/photo/1
• https://x.com/AdelaCastro222/status/1933832435839455637/photo/1

Results from open label extension of BE-OPTIMAL: -Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y. -No significant major tolerability issues or major SE. abstract #POS1294 #EULAR2025 @RheumNow https://t.co/VAEiciCR1z

• https://x.com/AdelaCastro222/status/1933834754052247622/photo/1

ICI-PMR irAEs are sometimes underestimated compared to inflamm arthritis, but why? ICI-IA and ICI-PMR look different, but at @HSpecialSurgery, steroid needs and disease impact for both are basically the same. Let’s not devalue either @lovetolearn27 #EULAR2025 POS1200 @RheumNow https://t.co/NVq2tpjvdu

• https://x.com/drdavidliew/status/1933835193514872898/photo/1
• https://x.com/drdavidliew/status/1933835193514872898/photo/1

#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL

• https://x.com/Yuz6Yusof/status/1933835385957675308/photo/1

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1
• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1
• https://x.com/AdelaCastro222/status/1933836201460445603/photo/1

Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq

• https://x.com/drdavidliew/status/1933837278289211854/photo/1